Format

Send to

Choose Destination
Int J Mol Sci. 2019 Sep 26;20(19). pii: E4789. doi: 10.3390/ijms20194789.

New Insights into Immunotherapy Strategies for Treating Autoimmune Diabetes.

Author information

1
Biochemistry Area, Health Science Department, Faculty of Health Sciences, Public University of Navarra, 31008 Pamplona, Spain. miriamcabelloolmo@gmail.com.
2
Biochemistry Area, Health Science Department, Faculty of Health Sciences, Public University of Navarra, 31008 Pamplona, Spain. miriam.arana@unavarra.es.
3
Diabetes research group at Sanford Research, Sioux Falls, SD 57104, USA. Ilian.Radichev@SanfordHealth.org.
4
Incyte Corporation, Wilmington, DE 19803, USA. PSmith@incyte.com.
5
Incyte Corporation, Wilmington, DE 19803, USA. EHuarte@incyte.com.
6
Biochemistry Area, Health Science Department, Faculty of Health Sciences, Public University of Navarra, 31008 Pamplona, Spain. miguel.barajas@unavarra.es.

Abstract

Type 1 diabetes mellitus (T1D) is an autoimmune illness that affects millions of patients worldwide. The main characteristic of this disease is the destruction of pancreatic insulin-producing beta cells that occurs due to the aberrant activation of different immune effector cells. Currently, T1D is treated by lifelong administration of novel versions of insulin that have been developed recently; however, new approaches that could address the underlying mechanisms responsible for beta cell destruction have been extensively investigated. The strategies based on immunotherapies have recently been incorporated into a panel of existing treatments for T1D, in order to block T-cell responses against beta cell antigens that are very common during the onset and development of T1D. However, a complete preservation of beta cell mass as well as insulin independency is still elusive. As a result, there is no existing T1D targeted immunotherapy able to replace standard insulin administration. Presently, a number of novel therapy strategies are pursuing the goals of beta cell protection and normoglycemia. In the present review we explore the current state of immunotherapy in T1D by highlighting the most important studies in this field, and envision novel strategies that could be used to treat T1D in the future.

KEYWORDS:

autoimmunity; diabetes; immunotherapy and clinical trials; insulin

PMID:
31561568
DOI:
10.3390/ijms20194789
Free full text

Supplemental Content

Full text links

Icon for Multidisciplinary Digital Publishing Institute (MDPI)
Loading ...
Support Center